MiNK Therapeutics, Inc.
INKTNasdaq
$10.66
↓ -1.4%Jul 17 close · end-of-day
Price
1Y↓ -53.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$51.1M
Enterprise Value
$41.6M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$12.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
98.3%
ROIC
—
Debt / Equity
—
Net Cash
$9.5M
Return 1Y
-54.1%
Company profile
MiNK Therapeutics, Inc. engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate, AGENT-797, is in Phase 1 clinical trials.
- CEO
- Jennifer S. Buell
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- New York
- Website
- minktherapeutics.com
Earnings
INKT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.57↓ -18.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$14.6M | -$28.4M | -$30.9M | -$22.9M | -$11.3M | -$12.6M |
| Net income | -$16.2M | -$30.2M | -$28.0M | -$22.5M | -$10.8M | -$12.5M |
| Diluted EPS | — | -$1.16 | -$0.83 | -$6.54 | -$2.86 | -$2.93 |
| Operating cash flow | -$8.3M | -$12.8M | -$18.9M | -$15.8M | -$9.6M | -$5.9M |
| Free cash flow | -$8.4M | -$13.1M | -$19.1M | -$15.8M | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.1M | -$1.9M | -$2.5M | -$2.7M | -$4.1M | -$3.2M | -$2.7M | -$2.9M |
| Net income | -$2.7M | -$1.8M | -$2.5M | -$2.8M | -$4.2M | -$2.9M | -$2.6M | -$2.7M |
| Diluted EPS | -$0.73 | -$0.46 | -$0.57 | -$0.70 | -$1.06 | -$0.65 | -$0.52 | -$0.57 |
| Operating cash flow | -$2.3M | -$3.0M | -$1.7M | -$1.3M | -$1.6M | -$941,348.00 | -$2.1M | -$1.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 3, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-04 | Ryan Barbara | Sale | 1,000 | $12.80 | $12,799.50 | filing |
| 2026-06-04 | Ryan Barbara | Sale | 500 | $12.68 | $6,341.75 | filing |
| 2026-06-01 | Corvese Brian | Award | 1,444 | $12.38 | $17,876.72 | filing |
| 2026-06-01 | Ryan Barbara | Award | 1,434 | $12.38 | $17,752.92 | filing |
| 2026-06-01 | Behner Peter | Award | 1,313 | $12.38 | $16,254.94 | filing |
| 2026-06-01 | WIINBERG ULF | Award | 1,131 | $12.38 | $14,001.78 | filing |
| 2026-06-01 | Holcomb John Bradley | Award | 1,091 | $12.38 | $13,506.58 | filing |
| 2026-03-10 | Ryan Barbara | Sale | 500 | $15.57 | $7,782.60 | filing |
| 2026-03-10 | Ryan Barbara | Sale | 500 | $15.30 | $7,650.00 | filing |
| 2026-03-10 | Ryan Barbara | Sale | 300 | $15.28 | $4,584.66 | filing |
| 2026-03-09 | Ryan Barbara | Sale | 200 | $10.17 | $2,034.50 | filing |
| 2026-03-02 | Corvese Brian | Award | 1,640 | $10.90 | $17,876.00 | filing |
| 2026-03-02 | Ryan Barbara | Award | 1,629 | $10.90 | $17,756.10 | filing |
| 2026-03-02 | Behner Peter | Award | 1,491 | $10.90 | $16,251.90 | filing |
| 2026-03-02 | WIINBERG ULF | Award | 1,285 | $10.90 | $14,006.50 | filing |
| 2026-03-02 | Holcomb John Bradley | Award | 1,239 | $10.90 | $13,505.10 | filing |
| 2026-03-02 | Ryan Barbara | Sale | 100 | $10.83 | $1,082.58 | filing |
| 2026-03-02 | Ryan Barbara | Sale | 100 | $10.83 | $1,082.58 | filing |
| 2026-02-27 | Ryan Barbara | Sale | 400 | $10.86 | $4,343.32 | filing |
| 2026-02-27 | Ryan Barbara | Sale | 400 | $10.86 | $4,343.32 | filing |
| 2026-01-02 | Buell Jennifer· Chief Executive Officer | Award | 31,474 | $11.12 | $349,990.88 | filing |
| 2026-01-02 | Buell Jennifer· Chief Executive Officer | Tax withholding | 10,024 | $11.12 | $111,466.88 | filing |
| 2025-12-01 | Corvese Brian | Award | 1,612 | $11.09 | $17,877.08 | filing |
| 2025-12-01 | Ryan Barbara | Award | 1,601 | $11.09 | $17,755.09 | filing |
| 2025-12-01 | Behner Peter | Award | 1,466 | $11.09 | $16,257.94 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.